1. Home
  2. WGSWW vs HUMAW Comparison

WGSWW vs HUMAW Comparison

Compare WGSWW & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

HOLD

Current Price

$0.01

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

N/A

Current Price

$0.09

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WGSWW
HUMAW
Founded
2017
2004
Country
United States
United States
Employees
1300
184
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WGSWW
HUMAW
Price
$0.01
$0.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
51.3K
16.9K
Earning Date
02-18-2025
03-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$305,450,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
50.79
N/A
52 Week Low
$0.00
$0.06
52 Week High
$0.17
$0.60

Technical Indicators

Market Signals
Indicator
WGSWW
HUMAW
Relative Strength Index (RSI) 42.02 49.46
Support Level $0.01 $0.09
Resistance Level $0.02 $0.10
Average True Range (ATR) 0.00 0.01
MACD 0.00 -0.00
Stochastic Oscillator 44.44 53.33

Price Performance

Historical Comparison
WGSWW
HUMAW

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: